Resmed Announces Results for the First Quarter of Fiscal 202

• Q1 revenue increased by 6% to $1.4 billion; up 7% on a core constant currency basis
• Q1 GAAP diluted earnings per share up 23% to $2.92; non-GAAP diluted EPS up 14% to $2.91
• Returned more than $1.0 billion to shareholders through share repurchases and dividends during Q1

Resmed Inc. announced its results for the quarter ended September 30, 2026, highlighting a 6% increase in revenue to $1.4 billion, with a 7% increase on a core constant currency basis. The company experienced a 23% rise in GAAP diluted earnings per share (EPS) to $2.92 and a 14% increase in non-GAAP diluted EPS to $2.91. Resmed also returned more than $1 billion to shareholders through share repurchases and dividends. The company's strong performance was attributed to global demand for its sleep and breathing health solutions and ongoing execution across its business. Resmed's Chairman and CEO, Mick Farrell, noted the company's growth in core constant currency revenue, expanded non-GAAP gross margin, and increased non-GAAP earnings per share.

FY 2027 Revenue: $5.75 - $5.85 Billion, Non-GAAP Diluted EPS: $12.00 - $12.25

Resmed plans to continue building its core sleep and breathing health businesses by extending the reach of its digital health ecosystem and connecting more people worldwide with life-saving treatment delivered in their own homes.